Chordate enrolls first patients in a randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the treatment of chronic non-allergic rhinitis 2018-05-08
Chordate enrolls first patients in a randomized, placebo-controlled, double-blind,
multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the
treatment of chronic non-allergic rhinitis
Data Anticipated Q4 2019
Kista, Sweden, May 08, 2018 — Chordate Medical Holding AB’s (publ) (“Chordate”), a specialty medtech company that
focuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis and
migraine, today announced that the first patients were enrolled in Chordate’s clinical study of its Kinetic Oscillation
Stimulation System S101 (KOS-treatment), an investigative product, in patients with diagnosed chronic non-allergic rhinitis.
“To now get started with the first patients at the University Hospitals in Helsinki and Kuopio, Finland, is very important in our
long-term securing of scientific evidence. We know from previous studies, and our own and others’ clinical experiences in
practice, that we make significant difference for this very large patient group. We are now building further on this with the
aim to produce a clear scientific basis for our continued business journey”, says Anders Weilandt, CEO of Chordate.
The randomized, placebo-controlled, double-blind, multicenter study is being conducted at fourteen ENT university clinics in
Finland, UK, The Netherlands, Italy and the Czech Republic. Coordinating investigator is Professor Claire Hopkins at Guys
Hospital, London and study advisor is Professor Mats Holmström at the Karolinska Institute, Stockholm. The study intends to
enroll up to 300 subjects and is designed to evaluate the efficacy and safety of the KOS-treatment. The primary endpoint is to
detect weekly median change in a set of evaluation criteria from baseline, with a series of two consecutive treatments, until
the third month follow-up visit. The total follow-up period of each patient is twelve months. Patients in the KOS arm will
receive active treatment from the S101, while patients receiving placebo treatment will be given a validated sham treatment
from the same equipment.
For more information, please contact:
Anders Weilandt, CEO
Phone: +46 (0) 733 87 42 77
This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse
Regulation. The information was provided, through the contact person above for publication on May 08, 2018 at. 14:45 CET.
TO THE EDITORS
Chordate Medical Holding AB (publ) is a medical technology company that during ten years has developed, patented and CEmarked
a new treatment method for chronic nasal congestion through nerve stimulation. The company sells its product
system including treatments through its own sales organization as well as distributors to clinics and hospitals, which in their
turn treat patients. Read more at www.chordate.com. Mangold Fondkommission AB, tel. +46 8 5030 1550, is the company’s
mentor and liquidity guarantee at NGM Nordic MTF.